Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 30,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 30,000 shares of Akero Therapeutics stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $52.73, for a total transaction of $1,581,900.00. Following the sale, the chief executive officer now owns 686,062 shares in the company, valued at approximately $36,176,049.26. This represents a 4.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Cheng also recently made the following trade(s):

• On Monday, January 27th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.90, for a total transaction of $1,647,000.00.
• On Tuesday, December 10th, Andrew Cheng sold 7,855 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total value of $241,855.45.
• On Monday, December 2nd, Andrew Cheng sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.09, for a total transaction of $802,250.00.

Akero Therapeutics Stock Down 0.4 %

AKRO opened at $49.23 on Friday. The company has a market capitalization of $3.44 billion, a PE ratio of -13.13 and a beta of -0.11. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The business has a 50-day moving average of $34.18 and a 200-day moving average of $30.53.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. HC Wainwright lifted their price target on shares of Akero Therapeutics from $50.00 to $72.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $35.00 to $63.00 in a research report on Thursday, January 30th. Canaccord Genuity Group increased their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. UBS Group upped their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a research note on Friday, January 31st. Finally, Citigroup raised their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $75.86.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP lifted its holdings in Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of Akero Therapeutics by 2.9% during the 3rd quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock worth $203,053,000 after buying an additional 201,225 shares during the period. RTW Investments LP boosted its holdings in shares of Akero Therapeutics by 9.0% during the 3rd quarter. RTW Investments LP now owns 5,919,435 shares of the company’s stock worth $169,829,000 after buying an additional 487,450 shares during the period. Vanguard Group Inc. grew its stake in Akero Therapeutics by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 3,704,411 shares of the company’s stock valued at $103,057,000 after buying an additional 27,830 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Akero Therapeutics in the 3rd quarter worth $37,392,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.